MRVI Maravai LifeSciences Holdings

Maravai LifeSciences To Host Earnings Conference Call on Thursday, February 22, 2024

Maravai LifeSciences To Host Earnings Conference Call on Thursday, February 22, 2024

SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, February 22, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 and reference Maravai LifeSciences, Conference ID 4939675. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at .

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.



Contact Information:
Deb Hart
Maravai LifeSciences
 7
EN
29/01/2024

Underlying

MRVIMaravai LifeSciences Holdings

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Maravai LifeSciences Holdings

 PRESS RELEASE
Free
MRVI Maravai LifeSci...

Maravai LifeSciences Reports Second Quarter 2025 Financial Results

Maravai LifeSciences Reports Second Quarter 2025 Financial Results Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings Quarterly base business revenue, which excludes revenue from high-volume CleanCap® for commercialized vaccine programs, grew 5% year-over-year Net Loss Reduction, Positive Adjusted EBITDA and Positive Free Cash Flow expected by second half 2026 SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life s...

August 11, 2025 1 EN
 PRESS RELEASE
Free
MRVI Maravai LifeSci...

Maravai LifeSciences To Host Earnings Conference Call on Monday, Augus...

Maravai LifeSciences To Host Earnings Conference Call on Monday, August 11, 2025 SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2025 financial and operating results after the market close on Monday, August 11, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (800) 267-6316 or (203) 518-9783 and reference Maravai LifeSciences, Conf...

July 28, 2025 1 EN
 PRESS RELEASE
Free
MRVI Maravai LifeSci...

Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Offic...

Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Rajesh “Raj” Asarpota has been appointed Executive Vice President (EVP) and Chief Financial Officer (CFO), effective June 30, 2025. He will succeed Kevin Herde, who is transitioning to an advisory role on the same date to support an effective transition.  “We thank Kevin for his commitment to Maravai and his...

June 25, 2025 1 EN
 PRESS RELEASE
Free
MRVI Maravai LifeSci...

Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer a...

Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William “Trey” Martin III in these roles. “This leadership transition reflects Maravai’s commitment to accelerating innovation, execut...

June 9, 2025 1 EN
 PRESS RELEASE
Free
MRVI Maravai LifeSci...

CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the ...

May 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch